Combinatorial library methods not only offer great potential for facilitating the drug discovery process but also provide powerful tools for basic research in various disciplines. These methods enable investigators to generate large number of chemical compounds that can be used as valuable source for the discovery of drug leads, molecular imaging agents, and capturing agents for molecular markers. In the area of basic research, large collections of chemical compounds can be used to probe their effects on specific cellular function. In the past 4 years, the combinatorial chemistry developing core has been assisting several Cancer Center investigators in the application of combinatorial chemistry to their research. These efforts have resulted in the submission and funding of several extramural grants. Based on the encouraging outcome and suggestion by our external advisory board, we plan to advance the combinatorial developing core to a full shared resource. The proposed combinatorial chemistry shared resource (CCSR7) will provide training and support for cancer center members to apply the ultra-high throughput one-bead-one-compound (OBOC) technologies for their research. Many OBOC combinatorial libraries (peptides, peptidomimetic, glycopeptides, small molecules, macrocyclic and glyco-organic libraries) will be designed and synthesized by the CCSR7 scientists. We have proposed to develop twenty-seven OBOC chemical libraries over the five year period. CCSR7 will also provide synthetic organic and medicinal chemistry expertise on working with the resource users for optimization of the lead compounds. CCSR7 will also provide synthetic organic and medicinal chemistry expertise on working with the resource users for optimization ofthe lead compounds.

Public Health Relevance

Through training and support by CCSR7, cancer center investigators will have the opportunity to apply the enabling OBOC combinatorial technology for their research. It is expected that chemical molecules useful for cancer research and lead compounds for the development of cancer therapeutic and imaging agents will be discovered through such efforts.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA093373-12
Application #
8743651
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
12
Fiscal Year
2014
Total Cost
$93,378
Indirect Cost
$32,540
Name
University of California Davis
Department
Type
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Shih, Tsung-Chieh; Liu, Ruiwu; Wu, Chun-Te et al. (2018) Targeting Galectin-1 Impairs Castration-Resistant Prostate Cancer Progression and Invasion. Clin Cancer Res 24:4319-4331
Weiss, Robert H (2018) Metabolomics and Metabolic Reprogramming in Kidney Cancer. Semin Nephrol 38:175-182
Hegde, John V; Shaverdian, Narek; Daly, Megan E et al. (2018) Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: Findings from a phase 2 trial. Cancer 124:521-529
Arun, Adith S; Tepper, Clifford G; Lam, Kit S (2018) Identification of integrin drug targets for 17 solid tumor types. Oncotarget 9:30146-30162
Tepper, Clifford G; Dang, Julie H T; Stewart, Susan L et al. (2018) High frequency of the PNPLA3 rs738409 [G] single-nucleotide polymorphism in Hmong individuals as a potential basis for a predisposition to chronic liver disease. Cancer 124 Suppl 7:1583-1589
Jerant, Anthony; Fenton, Joshua J; Kravitz, Richard L et al. (2018) Association of Clinician Denial of Patient Requests With Patient Satisfaction. JAMA Intern Med 178:85-91
Kirschbaum, Mark H; Frankel, Paul; Synold, Timothy W et al. (2018) A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study. Br J Haematol 180:445-448
Besprozvannaya, Marina; Dickson, Eamonn; Li, Hao et al. (2018) GRAM domain proteins specialize functionally distinct ER-PM contact sites in human cells. Elife 7:
Turner, David C; Kondic, Anna G; Anderson, Keaven M et al. (2018) Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance. Clin Cancer Res 24:5841-5849
Matsumoto, Collin; Jiang, Yan; Emathinger, Jacqueline et al. (2018) Short Telomeres Induce p53 and Autophagy and Modulate Age-Associated Changes in Cardiac Progenitor Cell Fate. Stem Cells 36:868-880

Showing the most recent 10 out of 836 publications